CHMP Positive On Trajenta, Vectibix, Votubia And Eurartesim, But Negative On Bronchitol, Luveniq And Glybera
This article was originally published in The Pink Sheet Daily
Executive Summary
Europe's scientific advisory panel recommends Boehringer Ingelheim's Trajenta and Novartis's Votubia for approval, and clears new indications for Amgen's Vectibix.